Core Laboratories (NYSE:CLB – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.120-0.200 for the period, compared to the consensus EPS estimate of 0.170. The company issued revenue guidance of $128.5 million-$135.5 million, compared to the consensus revenue estimate of $132.5 million.
Core Laboratories Stock Up 2.5%
Shares of CLB traded up $0.26 on Friday, hitting $10.61. The company’s stock had a trading volume of 165,580 shares, compared to its average volume of 590,620. The firm’s fifty day moving average price is $12.08 and its 200-day moving average price is $15.26. Core Laboratories has a fifty-two week low of $9.72 and a fifty-two week high of $20.36. The company has a quick ratio of 1.50, a current ratio of 2.05 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $489.12 million, a price-to-earnings ratio of 18.95, a P/E/G ratio of 2.38 and a beta of 1.00.
Core Laboratories (NYSE:CLB – Get Free Report) last announced its earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.08 by $0.03. Core Laboratories had a net margin of 5.10% and a return on equity of 10.06%. The firm had revenue of $124.61 million for the quarter, compared to the consensus estimate of $126.26 million. During the same period last year, the company posted $0.19 EPS. The business’s quarterly revenue was down 4.3% on a year-over-year basis. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. On average, equities research analysts expect that Core Laboratories will post 0.53 EPS for the current year.
Core Laboratories Dividend Announcement
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on CLB shares. Weiss Ratings lowered shares of Core Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. Wall Street Zen downgraded Core Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.
Check Out Our Latest Analysis on CLB
Institutional Trading of Core Laboratories
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd bought a new position in Core Laboratories in the fourth quarter valued at approximately $34,000. Quarry LP grew its stake in shares of Core Laboratories by 118.1% in the third quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock valued at $36,000 after buying an additional 1,599 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Core Laboratories by 400.9% in the second quarter. Tower Research Capital LLC TRC now owns 7,333 shares of the oil and gas company’s stock valued at $84,000 after buying an additional 5,869 shares in the last quarter. Vestcor Inc acquired a new position in Core Laboratories during the third quarter worth $101,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Core Laboratories during the third quarter worth $132,000. Institutional investors own 97.81% of the company’s stock.
About Core Laboratories
Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.
The company’s portfolio spans two primary service lines: reservoir description and production enhancement.
Featured Stories
- Five stocks we like better than Core Laboratories
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
- Peeling Out or Breaking Down? Ford’s High-Stakes Turnaround
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
